Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 8 Most Promising Biotech Stocks to Buy Now.

On May 8, Evercore ISI raised its price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $130 from $125. It maintained an “Outperform” rating on the stock.

On May 7, BridgeBio Pharma, Inc. (NASDAQ:BBIO) posted first-quarter 2026 results, showing $194.5 million in total revenue. The revenue comprised of $180.6 million from U.S. Attruby net product sales, fueled by prescribing growth and patient persistence.

The company said demand grew across patient types, pointing out strong uptake among treatment-naive patients. It noted global traction following a Brazil approval.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) said real-world evidence showed Attruby reduced diuretic intensification by 43% versus tafamidis, citing an analysis released on medRxiv and an independent study presented at SCAI.

Pipeline activity continued, with the company stating it submitted an NDA for BBP-418 and plans filings for encaler​​et and infigratinib in 2026.

The firm reported $940.2 million in cash as of March 31 and authorized a $500 million share repurchase program.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) identifies and promotes novel medications to treat Mendelian diseases. Its development pipeline contains product candidates at various stages of development, from early discovery to late-stage development.

While we acknowledge the risk and potential of BBIO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BBIO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.